Status:
UNKNOWN
Comparison of Sugammadex and Sugammadex-neostigmine Combination in the Antagonism of Moderate Neuromuscular Block
Lead Sponsor:
Ankara City Hospital Bilkent
Conditions:
Residual Neuromuscular Block
Neuromuscular Blockade Monitoring
Eligibility:
FEMALE
18-65 years
Phase:
NA
Brief Summary
In this prospective randomized controlled study the investigators compare the sugammadex-neostigmine combination and single dose sugammadex in terms of side effects and cost for the antagonism of mode...
Detailed Description
Sugammadex is a novel drug used to reverse neuromuscular blockade. It shows its effect by binding with steroid neuromuscular agents at a ratio of 1:1. Compared to anticholinesterase and other neuromus...
Eligibility Criteria
Inclusion
- elective general anesthesia
- Female gender
- Between the ages of 18-65
Exclusion
- ASA ≥ 3
- Pregnancy
- Contraindication to use of anesthetic drugs
- Kidney failure
- Liver failure
- Heart failure
- BMI \<18 and BMI \> 35 kg/m2
- anticipated difficult airway
- neuromuscular disease
- Use of drugs that impair neuromuscular transmission
- Patients who develop unexpected massive hemorrhage
- Those who do not have the ability to read, understand and sign the consent form
- Refusal of patient
Key Trial Info
Start Date :
February 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2022
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT05228223
Start Date
February 1 2022
End Date
June 1 2022
Last Update
February 8 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ankara City Hospital
Ankara, Turkey (Türkiye), 06800